Physician profile
Matthew Schilling
NPI 1861871204
$9,324.98
in general payments reported to CMS, 2019-2025
23 companies · $996 in 2025
The $996 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $2,055 · 2021: $1,054 · 2022: $1,744 · 2023: $1,494 · 2024: $1,459 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.83 |
| Education | $247.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,772.89 | 2019-2025 | Veklury, Biktarvy, Sunlenca |
| Cipla USA INC. | $1,502.51 | 2020 | |
| Paratek Pharmaceuticals, INC. | $1,211.76 | 2020-2025 | Nuzyra |
| Insmed, INC. | $1,187.87 | 2019-2024 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $563.32 | 2020-2024 | Vibativ |
| Astellas Pharma US INC | $440.87 | 2022-2025 | Cresemba |
| Viiv Healthcare Company | $409.20 | 2020-2024 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $385.90 | 2022-2025 | |
| Shionogi INC | $364.91 | 2021-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $333.84 | 2020-2025 | Zerbaxa, Dificid, Recarbrio |
| Melinta Therapeutics, LLC | $249.52 | 2021-2024 | Kimyrsa, Orbactiv, Rezzayo |
| Grt US Holding, INC. | $176.05 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $147.18 | 2022-2025 | Rebyota |
| La Jolla Pharmaceutical Company | $142.41 | 2022-2023 | Xerava |
| Sanofi Pasteur INC. | $97.22 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $93.69 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $73.51 | 2019 | |
| Aimmune Therapeutics, INC. | $37.77 | 2024-2025 | Vowst |
| Tactile Systems Technology INC | $36.20 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $32.52 | 2024 | Hyqvia |
| Pfizer INC. | $22.58 | 2024 | |
| Tersera Therapeutics LLC | $22.40 | 2024 | Quzyttir |
| Janssen Pharmaceuticals, INC | $20.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Schilling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.